HRT Financial’s Dianthus Therapeutics DNTH Stock Holding History

HRT Financial’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,997	Closed	-$199K	–	2816
2025 Q1	$199K	Buy	+10,997	New	+$242K	﹤0.01%	2033
2024 Q2	–	Sell	-34,174	Closed	-$1.02M	–	2409
2024 Q1	$1.02M	Buy	+34,174	New	+$743K	0.01%	875
2022 Q1	–	Sell	-3,068	Closed	-$217K	–	3261
2021 Q4	$217K	Buy	3,068 +1,844	+151%	+$185K	﹤0.01%	2483
2021 Q3	$142K	Buy	+1,224	New	+$143K	﹤0.01%	2797
2020 Q1	–	Sell	-773	Closed	-$187K	–	891
2019 Q4	$187K	Buy	+773	New	+$144K	0.01%	956

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial's DNTH Position: Q2 2025 in Review

HRT Financial sold out of Dianthus Therapeutics (DNTH) in Q2 2025, closing a stake of 10,997 shares — an estimated $199K sold.

HRT Financial first reported a position in DNTH in Q4 2019 and held it in 5 quarters. The position peaked at $1.02M in Q1 2024. 102 funds tracked by Wall St. Rank hold DNTH as of Q2 2025.

HRT Financial reported no remaining Dianthus Therapeutics position as of Q2 2025 after selling out during the quarter.
HRT Financial sold 10,997 Dianthus Therapeutics shares in Q2 2025, an estimated $199K.
HRT Financial first reported a position in Dianthus Therapeutics in Q4 2019 and held it in 5 quarters.
HRT Financial's Dianthus Therapeutics position peaked at $1.02M in Q1 2024.
102 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.